Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICT-CF: Orkambi Efficacy Prediction in Cystic Fibrosis
NCT03894657Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lumacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Percentage of Forced Expiratory Volume in 1 second at Week 24. Started Dec 2019; status: completed.
02
Drugs
lumacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03894657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894657.